Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198146 · ClinicalTrials.gov registry record · Phase 2
Prevention of Diabetes Progression Trial (PDPT)
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00198146 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 40 participants.
The verdict
NCT00198146, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the efficacy and safety of daclizumab in preventing the progression of diabetes in children who have just been diagnosed with type I diabetes. Additional purposes of the study are to investigate the amount of drug in the children, how quickly it is eliminated from the blood, and analyze the effect of the drug on the immune reaction to diabetes.
Interventions
- DRUG Zenapax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2000-07 |
| Est. Completion | 2007-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00198146
The ClinicalTrials.gov registry entry for NCT00198146 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zenapax is the first listed.
NCT00198146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00198146 about?
NCT00198146 is a clinical study titled "Prevention of Diabetes Progression Trial (PDPT)". The primary purpose of this study is to determine the efficacy and safety of daclizumab in preventing the progression of diabetes in children who have just been diagnosed with type I diabetes. Additional purposes of the study are to investigate the amount of drug in the children, how quickly it is e...
What is the current status of trial NCT00198146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2000-07. Estimated completion is 2007-02-23.
What interventions are being tested in trial NCT00198146?
The interventions under investigation include: Zenapax (DRUG).
Who is sponsoring clinical trial NCT00198146?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.